NYSE: BLCO

Bausch + Lomb (BLCO) Stock Analysis & Forecast

Nov 13 close

$21.09−0.05 (−0.2%)

Gekko Brief

AI summaryNov 9 close

Bausch + Lomb moves higher this week after third-quarter results showed revenue of $1.375 billion and net income of $32 million, a swing from a loss a year earlier. All three segments grew, with constant-currency revenue up 8%, adjusted EBITDA up 34%, and margin expanding to 23.6%, led by Miebo, LUMIFY, and the contact lens portfolio. The company also raised full-year 2026 revenue guidance to a range of $5.45 billion to $5.55 billion, and commentary points to a falling net leverage ratio alongside the fourth consecutive quarter of this growth pattern.

The stock closes at $20.96, up 4.9%, sitting above both its 50-day average of $17.71 and 200-day average of $16.76, with the shorter average above the longer one. The GekkoIndex reads 44.1, placing the stock in the Distribution zone, and the price stands 29.9% above Gekko Fair Value of $16.13.

The next earnings date falls on 17 February 2027, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective windows, while two billionaire holders are recorded. Analyst consensus across 10 firms shows 4 buy, 5 hold, and 1 sell ratings, with a consensus target of $21.71. Seasonality over the next 20 trading days has averaged -0.4% across 4 years, rising in 3 of them, a mixed historical pattern worth noting alongside the current gap to fair value.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Bausch + Lomb price vs fair value

$21.09$16.49Nov ’25May ’26Nov ’26
Close $21.09200-day averageGekko Fair Value $16.49

Bausch + Lomb quick facts

Market cap
$7.54B
P/E ratio
—
Forward P/E
18.4
EPS, TTM
−$0.32
Revenue, TTM
$5.42B
Profit margin
-2.1%
Dividend yield
—
Beta
0.52
Volume
524,940 avg 1.04M
1-year return
+27.0%
Typical daily move
±3.8%
Typical 20-day move
±5.3%
50-day average
$17.98
200-day average
$16.85
Next earnings
Feb 17 before open
Shares outstanding
357.5M
52-week range
$14.44$21.40

Bausch + Lomb swing-trade checklist

Bausch + Lomb scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $21.09 is above the 50-day ($17.98) and 200-day ($16.85) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    45.4, Neutral

    Reading 45.4 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    27.9% above

    Price is 27.9% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 94 days

    Next report Feb 17, 2027, 94 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +1.1% on average

    From this point in the calendar, the next 20 trading days averaged +1.1% over 4 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Bausch + Lomb stock chart and price history

Bausch + Lomb closed at $21.09 on Nov 13, 2026, +27.0% over the past year, inside a 52-week range of $14.44 to $21.40.

Close50-day average200-day averageVolume
Bausch + Lomb share price, past year, with 50-day and 200-day moving averages and volume$14$16$18$20DecJan 2026FebMarAprMayJunJulAugSepOctNov21.09

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+26.6%
3 months
+24.1%
6 months
+31.1%
1 year
+27.0%
The full BLCO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BLCO in Gekko

Follow Bausch + Lomb through every session

Put BLCO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track BLCO in GekkoFree for 7 days. No credit card required.

About Bausch + Lomb

Bausch + Lomb focuses on eye health, offering products that range from everyday vision correction to treatments for diseased or post-surgical eyes. The company is widely recognized for its contact lenses, which span daily disposables through longer-wear options, alongside lens care solutions, over-the-counter eye drops and supplements addressing issues like dryness, allergies and conjunctivitis.

The business is divided into three areas. One covers vision care and consumer eye health products. Another, Ophthalmic Pharmaceuticals, develops branded and generic prescription drugs for conditions such as glaucoma, ocular hypertension and retinal disease, along with therapeutic contact lenses used post-surgery. The third, Surgical, supplies equipment for cataract and retinal procedures, including intraocular lenses, delivery systems, phacoemulsification devices and other surgical instruments.

Bausch + Lomb traces its founding back to 1853 and operates out of Vaughan, Canada. Its shares are listed on the NYSE under the ticker BLCO.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
bausch.com

Bausch + Lomb GekkoIndex: the smart money zone

Bausch + Lomb’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45.4, in the Neutral zone, up 0.1 points over five sessions.

010045.4Neutral

Up 0.1 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying39+0.5%+0.3%+4.1%−0.2%
Accumulation212+0.8%+1.6%+0.8%+0.9%
Neutral (current zone)401+0.4%+0.7%+1.3%+3.0%
Distribution42−1.1%−2.6%−2.4%+1.0%
Selling8Too few readings yet

Average BLCO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the BLCO price, zone by zone.Track BLCO in Gekko

Is Bausch + Lomb stock overvalued? Gekko Fair Value

Bausch + Lomb trades 27.9% above Gekko Fair Value of $16.49, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Bausch + Lomb shares are worth, recalculated every trading day.

$16.49

Gekko Fair Value, Nov 14, 2026

27.9% Overvalued

At the end of Sep 2026 the price was 17.6% above the estimate.

Gekko Fair ValueShare price, month end
$16$21Sep 2026OctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open BLCO in Gekko

Bausch + Lomb insider and Congress trading

No open-market insider purchases were filed for Bausch + Lomb, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for BLCO in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every BLCO insider filing, plotted on the chart in Gekko.Open BLCO in Gekko

Congress trades last 90 days

No trades in BLCO were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for BLCO, plotted on the chart in Gekko.Open BLCO in Gekko

Buybacks

Bausch + Lomb has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$27.00M
As a share of market cap
0.36%

From company filings.

Hedge funds and billionaires quarter ended Sep 30

1of the funds Gekko tracks holds BLCO.

0added0opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Bausch + Lomb earnings: next date and track record

Bausch + Lomb reports on Feb 17, 2027, before the open (94 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±5.7%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−2.8%Feb ’25−15.5%Apr ’25−7.0%Jul ’25−0.4%Oct ’25−0.5%Feb ’26+1.1%Apr ’26+2.3%Jul ’26+15.8%Oct ’26

Last earnings call, Oct 28, 2026 AI summary

What they said
Bausch and Lomb reported Q3 2026 results with 8% constant currency revenue growth, 34% adjusted EBITDA increase, and adjusted EBITDA margin expansion to 23.6%. All three segments grew: Pharmaceuticals +11%, Surgical +9%, and Vision Care +6% on constant currency basis. Key growth drivers included Miebo, LUMIFY, and contact lens portfolio (Infuse and Ultra). This marks the fourth consecutive quarter of meeting Investor Day commitments.
Guidance
Management reaffirmed commitment to meeting or exceeding Vision 27 three-year plan targets. Priorities include improving profitability, margin expansion, and cash generation while continuing pipeline investment in dry eye, surgical technologies, and next-generation contact lenses.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 28, 2026$0.34
est $0.21
+58.5%$1.38B
est $1.37B
+0.2%+15.8%
Jul 29, 2026$0.16
est $0.15
+3.6%$1.39B
est $1.37B
+1.8%+2.3%
Apr 29, 2026$0.08
est $0.06
+33.3%$1.24B
est $1.22B
+2.3%+1.1%
Feb 18, 2026$0.32
est $0.35
−8.6%$1.41B
est $1.39B
+1.4%−0.5%
Oct 29, 2025$0.18
est $0.16
+12.5%$1.28B
est $1.38B
−7.4%−0.4%
Jul 30, 2025$0.07
est $0.06
+16.7%$1.28B
est $1.27B
+0.3%−7.0%
Apr 30, 2025−$0.07
est $0.03
−333.3%$1.13B
est $1.25B
−9.6%−15.5%
Feb 19, 2025$0.25
est $0.24
+4.2%$1.28B
est $1.15B
+11.2%−2.8%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Bausch + Lomb stock forecast and analyst price targets

Analysts’ average 12-month price target for Bausch + Lomb is $21.71, +2.9% from the last close, from 10 firms rating the stock in the last 90 days.

$21.71consensus 12-month target, +2.9% from the last close
Low $18High $26
Buy4
Hold5
Sell1

Each firm’s latest rating in the last 90 days: 10 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 2H.C. WainwrightHold, downgraded$22+4.3%
Oct 29CitiBuy, maintained$23+9.1%
Oct 29RBC CapitalBuy, reiterated$23+9.1%
Oct 29J.P. MorganHold, maintained$22+4.3%
Oct 29Bank of America SecuritiesSell, maintained——
+1.3%average 20-day move after past Neutral readings
+1.1%average move over the next 20 trading days in the last 4 years
±3.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Bausch + Lomb seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Bausch + Lomb averaged +1.1% across the last 4 years, rising in 2 of them.

Next 20 trading days, by year

+5.6%2022−5.0%2023−5.0%2024+9.6%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−3.6%0 of 4
Next 10 trading days−0.8%2 of 4
Next 15 trading days0.0%2 of 4
Next 20 trading days+1.1%2 of 4
Next 30 trading days+0.3%2 of 4

For scale, BLCO’s typical 20-trading-day move in either direction is about 5.3%.

Bausch + Lomb market cap and key statistics

Bausch + Lomb’s market cap is $7.54B and revenue of $5.42B over the last twelve months.

Valuation

Market cap
$7.54B
Forward P/E
18.4
EPS, TTM
−$0.32
Gekko Fair Value
$16.49

Trading

Volume
524,940
Avg volume, 20 days
1.04M
52-week high
$21.40
52-week low
$14.44
Shares outstanding
357.5M

Financials

Revenue, TTM
$5.42B
Profit margin
-2.1%
Return on equity
-1.6%
Quarterly earnings growth, YoY
−88.6%

Risk and income

Beta
0.52
Typical daily move
±3.8%
Typical 20-day move
±5.3%

Bausch + Lomb stock news this week

Coverage of Bausch + Lomb this week reads positive: 4 positive, 3 neutral and 0 negative headlines.

News sentiment positive

Bausch + Lomb peers

Bausch + Lomb’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Bausch + Lomb stock FAQ

What is Bausch + Lomb’s market cap?

Bausch + Lomb’s market cap is $7.54B at the Nov 13, 2026 close of $21.09, with 357.5M shares outstanding.

What is the Bausch + Lomb stock forecast?

The consensus analyst 12-month price target for Bausch + Lomb is $21.71, +2.9% from the last close. Of the 10 firms that rated the stock in the last 90 days, 4 rate it a buy, 5 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is Bausch + Lomb stock overvalued or undervalued?

On Gekko’s estimate Bausch + Lomb is overvalued: the Nov 13, 2026 close of $21.09 is 27.9% above Gekko Fair Value of $16.49. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Bausch + Lomb report earnings next?

Bausch + Lomb is expected to report on Feb 17, 2027, before the market opens (94 days away). Analysts expect earnings of $0.36 per share on revenue of $1.49B. Bausch + Lomb beat the earnings estimate in 6 of its last 8 reports, moving 5.7% on average across the report.

What is Bausch + Lomb’s 52-week high and low?

Bausch + Lomb’s 52-week high is $21.40 and its 52-week low is $14.44; it closed at $21.09 on Nov 13, 2026, +27.0% over the past year. Over the last five years the shares peaked at $21.95 on Jun 30, 2023.

Is Bausch + Lomb stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Bausch + Lomb the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.